In this study, we have shown that BC cases with AR/ER ratio ≥ 2 (assessed by IHC and qPCR) are characterized by an increased proliferation status defined by a pooled gene expression analysis of AURKA, BIRC5, CCNB1, MKI67 and UBE2C proliferation markers. This evidence concerns the gene AURKA and breast cancer.